ImmuPharma plc (LON:IMM – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 5.99 and traded as low as GBX 5.72. ImmuPharma shares last traded at GBX 6, with a volume of 4,228,961 shares changing hands.
ImmuPharma Stock Performance
The stock’s fifty day simple moving average is GBX 10.11 and its 200-day simple moving average is GBX 5.99. The stock has a market cap of £30.16 million, a P/E ratio of -6.74 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Comparing and Trading High PE Ratio Stocks
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- There Are Different Types of Stock To Invest In
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- Do ETFs Pay Dividends? What You Need to Know
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
